Oportun Financial Corporation posted a 3% year-over-year revenue increase in Q3 2026, marking its first growth since late 2023. The company saw a 12% rise in loan originations, improved net income to $23 million, and lowered its net charge-off rate to 10.6%. Oportun introduced its 'Oportun Forward' strategy to simplify operations and drive sustainable growth. It raised its full-year revenue guidance to $955-$960 million and expects adjusted EPS of $1.60 to $1.70, reflecting confidence in continued profitability and disciplined credit management.
Oportun Financial Corporation's recent report highlights a 12% increase in loan originations, signaling growth momentum. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 04, 2026 04:02 WIB: out of 142 priced US Financials stocks, 59 rose and 83 fell. Notable movers include APO at USD 114.11 with a 1-day change of -4.48% and Pluang order activity skewed 21% Sell / 79% Buy, PSEC at USD 1.55 down 4.32% with 80% Sell / 20% Buy activity, and PURR at USD 10.09 up 3.91% with 15% Sell / 85% Buy activity and a typical hold time of 4 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
